BillionToOne (BLLN)
Financials 
Technical Analysis 
Sep 4, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
BillionToOne, with the symbol BLLN-Q, has drawn significant attention following its impressive IPO and strong fundamentals. The company specializes in genetic tests aimed at early disease detection, leveraging technology that is reportedly more advanced than its competitors. Since its inception, BillionToOne has experienced remarkable sales growth, boasting a compounded annual growth rate of 167% since 2021 and a striking 113% revenue increase over the past year. Their outlook remains strong with Q3 guidance predicting revenue growth between 112-120%. Additionally, the EBITDA turned positive earlier this year, indicating a shift towards profitability. Despite these positive attributes, the stock has faced recent volatility, prompting some investors to suggest waiting for a price dip to enhance its attractiveness.
- «
- ‹
- 1
- ›
- »
Popular Articles
BillionToOne (BLLN) Frequently Asked Questions
What is BillionToOne stock symbol?
BillionToOne is a OTC stock, trading under the symbol BLLN (previously BLLN-Q on Stockchase) on the undefined (undefined). It is usually referred to as or BLLN
Is BillionToOne a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on BLLN (previously BLLN-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PARTIAL BUY. Read the latest stock experts' ratings for BillionToOne.
Is BillionToOne a good investment or a top pick?
BillionToOne was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for BillionToOne.
Why is BillionToOne stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for BillionToOne.
Is BillionToOne worth watching?
BillionToOne is covered by Stockchase experts and is worth watching.
They had an impressive IPO recently. They make genetic tests to detect diseases early. Their technology is superb and is ahead of their competition. Since 2021, sales have been rising at 167% compounded annually. Last year saw 113% revenue growth. Q3 guidance declared revenue growth at 112-120%. EBITDA turned positive earlier this year. Excellent growth and profitable. Also, they have a clean balance sheet. However, the stock has already seen a pullback, so there's volatility. Wants to see shares fall further to make it more attractive.